Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating activities:
Net income	$ 76,180	$ 168,669
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	20,799	17,271
Acquired in-process research & development	115,986
Bad debt recoveries	(19)	(192)
Stock-based compensation	40,740	33,719
Write-down of inventory and other	8,899	5,078
Accretion on marketable securities	2,701	1,183
Change in fair value of other investments	(14,265)	(43,107)
Gain on previously held interest in preCARDIA	(20,980)
Deferred tax provision	7,049	22,920
Change in fair value of contingent consideration	(833)	3,016
Other non-cash operating activities	2,331	3,194
Changes in assets and liabilities:
Accounts receivable	7,662	(6,925)
Inventories	(19,569)	6,596
Prepaid expenses and other assets	(11,874)	(7,061)
Accounts payable	(2,481)	(8,147)
Accrued expenses and other liabilities	(6,589)	(10,000)
Deferred revenue	681	1,889
Net cash provided by operating activities	206,418	188,103
Investing activities:
Purchases of marketable securities	(581,849)	(487,753)
Proceeds from the sale and maturity of marketable securities	404,193	338,331
Purchases of other investments and intangible assets	(7,067)	(26,104)
Proceeds from sales of Shockwave Medical securities		67,882
Purchases of property and equipment	(20,872)	(27,274)
Net cash used for investing activities	(288,416)	(187,101)
Financing activities:
Proceeds from the exercise of stock options	8,822	7,076
Taxes paid related to net share settlement upon vesting of stock awards	(16,396)	(11,176)
Payment of Breethe contingent consideration at acquisition date fair value	(2,334)
Repurchase of common stock		(11,310)
Proceeds from the issuance of stock under employee stock purchase plan	2,961	1,978
Net cash used for financing activities	(6,947)	(13,432)
Effect of exchange rate changes on cash and cash equivalents	490	1,107
Net decrease in cash and cash equivalents	(88,455)	(11,323)
Cash and cash equivalents at beginning of period	232,710	192,341
Cash and cash equivalents at end of period	144,255	181,018
Supplemental disclosure of cash flow information:
Cash paid for income taxes	50,378	34,024
Supplemental disclosure of non-cash activities:
Contingent consideration related to the acquisition of Breethe		13,300
Property and equipment in accounts payable and accrued expenses	1,433	640
Right-of-use assets obtained in exchange for lease liabilities	5,397	1,378
Precardia
Investing activities:
Payments for acquisition	$ (82,821)
Breethe
Investing activities:
Payments for acquisition		$ (52,183)